Resistance of Targeted Therapies Excluding Antibodies for Lymphomas

• Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
• Άλλοι συγγραφείς: Ferreri, Andrés J. M. (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt)
• Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
• Γλώσσα: English
• Έκδοση: Cham : Springer International Publishing : Imprint: Springer, 2018.
• Έκδοση: 1st ed. 2018.
• Σειρά: Resistance to Targeted Anti-Cancer Therapeutics, 17
• Θέματα: Cancer research.; Molecular biology.; Cancer Research.; Molecular Medicine.

In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these thera...

Πίνακας περιεχομένων:

• Chapter 1 BTK inhibitors: focus on ibrutinib and similar agents
• Chapter 2 BCL2 Inhibitors: insights into resistance
• Chapter 3 Proteasome Inhibitors with a Focus on Bortezomib
• Chapter 4 IMiD - immunomodulatory drug lenalidomide (CC-5013; Revlimid) in the treatment of lymphoma: Insights into clinical use and molecular mechanisms
• Chapter 5 mTOR inhibitors, with special focus on temsirolimus and similar agents
• Chapter 6 Inhibitors of the JAK/STAT pathway, with a focus on ruxolitinib and similar agents.